Dexcom reports clear analyst support, shares trade below new Deutsche Bank target
26.06.2026 - 15:09:20 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 15:08.
Dexcom Inc. (US2521311074) is drawing renewed attention after a fresh analyst call. Deutsche Bank has initiated coverage on the NASDAQ-listed diabetes technology specialist with a Buy rating and an $86 price target, adding to a generally favorable consensus backdrop. MarketScreener note on the Deutsche Bank initiation
What Deutsche Bank is signaling
According to the June 23 coverage initiation, Deutsche Bank started Dexcom with a Buy recommendation and set the price target at $86 per share, implying notable upside versus recent trading levels. Dexcom investor information This call comes with Dexcom shares last closing at $68.65 on NASDAQ on June 25, 2026, which is roughly 20 percent below the new target. TradingKey real-time quote for DXCM
Trading data for June 25 show Dexcom shares opened at $69.88, reached an intraday high of $70.79 and touched a low of $68.58 before ending the session at $68.65, a decline of 1.58 percent on the day. Session statistics for Dexcom shares That places the stock closer to the lower end of its recent 50-day range between roughly $57.56 and $78.19, according to aggregated market data. MarketBeat overview for DexCom
How the broader analyst consensus looks
Deutsche Bank’s entry adds to an already constructive analyst picture. Aggregated data show Dexcom with an overall Buy consensus and an average price target in the mid-$80s per share, with one data provider citing $86.28 as the mean target and another listing $85.21, both clearly above the current market price. TradingKey consensus metrics for Dexcom PandaForecast summary of analyst expectations
Recent performance has been mixed but not dramatic. Over the five trading days to June 23, Dexcom’s shares eased modestly, with MarketScreener showing a 0.60 percent drop over that period and a 4.33 percent decline since the start of the year, while still posting a 3.67 percent gain over a longer comparative window. MarketScreener performance data for Dexcom
All news and analysis on the Dexcom shares
More background, price data and regulatory disclosures on Dexcom can be found in the dedicated topic section and on the company’s investor relations pages.
The business behind the stock
Dexcom generates its revenues primarily from continuous glucose monitoring systems for people with diabetes. Its flagship product line is the Dexcom G7 CGM system, which combines a small wearable sensor, a transmitter and a connected display on a smartphone or receiver to provide near real-time glucose readings and alerts. Dexcom product information on the G7 system
Where the Dexcom shares trade today
Dexcom Inc. shares (US2521311074) trade on NASDAQ under the ticker DXCM. As of 2026-06-25, 16:00 Eastern Time, the last regular-session price was $68.65 per share in US dollars. NASDAQ closing data for Dexcom
Dexcom at a glance
- Company: Dexcom Inc.
- ISIN: US2521311074
- WKN: A0D9T5
- Ticker: DXCM
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 16:00): 68.65 USD
- Market cap: 26.49 billion USD (as of 2026-06-25)
- Sector / industry: Health Care Equipment, Medical Instruments
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article provides factual information and context on Dexcom Inc. shares and does not contain investment advice, recommendations or personalized financial guidance. Investors should conduct their own research or consult a licensed advisor before making investment decisions.
